England witnesses sharp rise in food allergy incidence
Pharmaceutical Technology
OCTOBER 10, 2024
According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
OCTOBER 10, 2024
According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.
Pharmaceutical Technology
SEPTEMBER 5, 2023
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 20, 2024
Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.
Pharmaceutical Technology
AUGUST 27, 2024
UCB has entered a divestment agreement in China to sell its mature neurology and allergy business to CBC Group and Mubadala for $680m.
Pharmaceutical Technology
DECEMBER 4, 2023
GlobalData tracks 4 drugs in development for Cat Allergy by four companies/universities/institutes. The top development phase for Cat Allergy is preclinical, with two drugs in that stage.
Pharmaceutical Technology
FEBRUARY 7, 2024
Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.
Pharmaceutical Technology
FEBRUARY 19, 2024
Allergen for Peanut Allergy is under clinical development by ALK-Abello and currently in Phase II for Peanut Allergy.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 13, 2023
More treatments – and faster-acting treatments – for peanut allergies are urgently needed, and a new study outlines a promising drug technology based around a tiny nanoparticle just a few billionths of a meter in size. In tests on mice, the nanoparticle reversed peanut allergies and prevented them from developing in the first place.
Pharmaceutical Technology
MAY 16, 2024
IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001.
Pharmaceutical Technology
NOVEMBER 23, 2023
The fast track designation for the paediatric multi-food allergy therapy ADP101 was based on the Phase I/II data.
Pharmaceutical Technology
DECEMBER 4, 2023
GlobalData tracks 11 drugs in development for Grass Pollen Allergy by ten companies/universities/institutes. The top development phase for Grass Pollen Allergy is phase ii, with six drugs in that stage.
Fierce Pharma
FEBRUARY 16, 2024
People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades.
XTalks
SEPTEMBER 27, 2024
Novartis and Genentech released a pair of new TV commercials for allergy and asthma drug Xolair (omalizumab) as part of a direct-to-consumer (DTC) nationwide campaign called “Accidents Happen.” The ad highlights that despite the care parents take in handling their children’s allergies, accidental exposure can happen.
pharmaphorum
FEBRUARY 19, 2024
Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in the US.
Fierce Pharma
DECEMBER 19, 2023
On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes. | On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes.
Pharmaceutical Technology
DECEMBER 22, 2023
Regeneron Pharmaceuticals Inc granted patent for preventing or treating allergies. Learn about the method involving IL-4R antagonists and specific dosage instructions.
Outsourcing Pharma
AUGUST 29, 2024
The European Commission has approved ARS Pharmaceuticalsâ adrenaline nasal spray for the emergency treatment of severe allergies, EURneffy.
XTalks
OCTOBER 6, 2022
According to the Asthma and Allergy Foundation of America, about 32 million people in the US have food allergies, which means allergy friendly food brands not only have a large audience base, but are also necessities. Partake Foods has become one of the most popular allergy friendly food brands and it recently secured $11.5
pharmaphorum
OCTOBER 10, 2022
For the 32 million individuals in the US with food allergies, more research into symptoms, causes, and treatments has been long sought after, but historically underfunded. per person being spent on food allergy research. Luckily for those with food allergies, the food allergy sector has benefitted from this influx of funding.
Medical Xpress
APRIL 4, 2023
Children with food allergies might experience heightened anxiety over social situations involving food. A Baylor College of Medicine psychologist explains how parents can alleviate this stress while teaching them to be mindful of their allergies.
Medical Xpress
MAY 9, 2023
Having a latex allergy is no fun, but it can be a real challenge for health professionals who have to work with a wide variety of medical equipment that can contain the allergen.
NY Times
DECEMBER 11, 2020
British health officials recommended that people with severe allergy reactions not be given the vaccine. Such reactions to vaccines are rare, even in people who have allergies to food or bee stings.
Medical Xpress
APRIL 6, 2023
Black and Hispanic patients with severe allergies are less likely to get a common treatment, allergen immunotherapy, compared to white patients, according to Penn State College of Medicine researchers.
Bio Pharma Dive
SEPTEMBER 5, 2023
The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.
Drug Patent Watch
FEBRUARY 12, 2024
Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There… The post New patent for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JUNE 7, 2024
Discover how compounding pharmacies use genetic information to create precision medications tailored to individual allergies. Learn how personalised treatments can benefit you.
NPR Health - Shots
APRIL 2, 2023
Patients who have digestive symptoms only after eating red meat may have developed an allergy caused by ticks. Previously, doctors looked for symptoms such as rashes, hives and breathing troubles. Image credit: Getty Images)
Medical Xpress
NOVEMBER 28, 2022
Philip Li from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has pioneered a new nurse-led penicillin allergy triage and testing strategy—the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI), and demonstrated its effectiveness and safety compared to traditional allergy testing.
Medical Xpress
MAY 3, 2023
A new Nature Immunology study led by University of Pittsburgh and National Institutes of Health researchers sheds light on how a rare type of helper T cell, called Th9, can drive allergic disease, suggesting new precision medicine approaches to treating allergies in patients with high levels of Th9.
Drug Patent Watch
MAY 24, 2024
Annual Drug Patent Expirations for CHILDREN%27S+ADVIL+ALLERGY+SINUS For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com Source
Trialfacts
JANUARY 23, 2024
More Study Details About the Study A peanut allergy can be severe and life-threatening if not treated promptly. Peanut allergies are one of the most common food allergies in children in the USA, with more than 2% of children being affected. Participants will receive a new potential treatment for their peanut allergy at no cost.
Fierce Pharma
SEPTEMBER 5, 2023
billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. After lackluster sales dampened the initial enthusiasm that came with a $2.1
Scienmag
DECEMBER 22, 2021
There have been many research efforts describing the nature and progression of dog allergies, but there have been very few applied studies that use this information to try to cure people of dog allergies entirely by artificially inducing immune tolerance.
Delveinsight
AUGUST 2, 2021
Peanut allergy (PA) is one of the most common food allergies that affect children in Western nations. Historically, the gold standard of the treatment for Peanut allergy constituted a strategic plan for peanut avoidance coupled with an adrenaline auto-injector (AAI) in case of contingencies.
Pharma Times
FEBRUARY 10, 2022
Research demonstrates that people who live with peanut allergies face isolation and discrimination
XTalks
JANUARY 17, 2023
The US Food and Drug Administration (FDA) has added sesame to its list of major allergens, making it easier for people with sesame allergies to safely consume packaged food without fear of an allergic reaction. Related: Top 3 Allergy Friendly Food Brands. percent of children and adults in the US are allergic to sesame.
Medical Xpress
DECEMBER 2, 2022
The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.
Medical Xpress
JANUARY 2, 2023
Keeping allergies and asthma in check in the new year is a resolution worth keeping.
Medical Xpress
MARCH 17, 2023
Peanut allergy could plummet by 77 percent if peanut products were added to all babies' diets at four to six months of age, according to new research led by the University of Southampton, Kings College London, and the National Institute for Health and Care Research (NIHR).
Medical Xpress
DECEMBER 16, 2022
Taking action to be evaluated for a penicillin allergy can impact your health, safety and wallet. population reports a penicillin allergy, but less than 1% is allergic after testing. According to the Centers for Disease Control and Prevention, 10% of the U.S. Common penicillins include ampicillin, amoxicillin and Augmentin.
Medical Xpress
MARCH 16, 2023
I have had allergies since childhood, suffering during both the spring and fall seasons. I'm beginning to wonder if my symptoms are really from allergies or if they may be caused by a sinus infection instead. This past month, however, I am experiencing more congestion and mucus, and I even have some facial pain.
Scienmag
JULY 5, 2022
Scientists have revealed the genetic and molecular structure of key molecules linked to the sometimes life-threatening mammalian-meat allergy brought on by tick bites. The […].
Outsourcing Pharma
SEPTEMBER 16, 2021
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
Scienmag
NOVEMBER 17, 2020
Credit: Eliot Herman Food allergies are a big problem. suffer from some kind of food allergy. These allergies cost a whopping $25 billion in health care each year. About 7% of children and 2% of adults in the U.S. Then there’s the time lost at school or work.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content